Dan P. Stephens
University of Texas Health Science Center at San Antonio
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Dan P. Stephens.
The Journal of Physiology | 2003
Lee Ann T. Bennett; John M. Johnson; Dan P. Stephens; Adham R. Saad; Dean L. Kellogg
Active vasodilatation (AVD) in human, non‐glabrous skin depends on functional cholinergic fibres but not on acetylcholine (ACh). We tested whether AVD is a redundant system in which ACh and vasoactive intestinal polypeptide (VIP) are co‐released from cholinergic nerves. (1) We administered VIP by intradermal microdialysis to four discrete areas of skin in the presence of different levels of the VIP receptor antagonist, VIP(10−28), also delivered by microdialysis. Skin blood flow (SkBF) was continuously monitored by laser Doppler flowmetry (LDF). Mean arterial pressure (MAP) was measured non‐invasively and cutaneous vascular conductance (CVC) calculated as LDF/MAP. Subjects were supine and wore water‐perfused suits to control whole‐body skin temperature (Tsk) at 34 °C. Concentrations of 54 μm, 107 μM, or 214 μM VIP(10−28) were perfused via intradermal microdialysis at 2 μl min−1 for approximately 1 h. Then 7.5 μM VIP was added to the perfusate containing VIP(10−28) at the three concentrations or Ringer solution and perfusion was continued for 45‐60 min. At the control site, this level of VIP caused approximately the vasodilatation typical of heat stress. All VIP(10−28)‐treated sites displayed an attenuated dilatation in response to the VIP. The greatest attenuation was observed at the site that received 214 μM VIP(10−28) (P < 0.01). (2) We used 214 μM VIP(10−28) alone and with the iontophoretically administered muscarinic receptor antagonist atropine (400 μA cm−2, 45 s, 10 mM) in heated subjects to test the roles of VIP and ACh in AVD. Ringer solution and 214 μM VIP(10−28) were each perfused at two sites, one of which in each case was pretreated with atropine. After 1 h of VIP(10−28) treatment, individuals underwent 45−60 min of whole‐body heating (Tsk to 38.5 °C). VIP(10−28), alone or in combination with atropine, attenuated the increase in CVC during heat stress, suggesting an important role for VIP in AVD.
Journal of Applied Physiology | 1999
Nisha Charkoudian; Dan P. Stephens; Kenna C. Pirkle; Wojciech A. Kosiba; John M. Johnson
American Journal of Physiology-heart and Circulatory Physiology | 2004
Dan P. Stephens; Adham R. Saad; Lee Ann T. Bennett; Wojciech A. Kosiba; John M. Johnson
American Journal of Physiology-heart and Circulatory Physiology | 2001
Dan P. Stephens; Ken Aoki; Wojciech A. Kosiba; John M. Johnson
Journal of Applied Physiology | 2001
Adham R. Saad; Dan P. Stephens; Lee Ann T. Bennett; Nisha Charkoudian; Wojciech A. Kosiba; John M. Johnson
American Journal of Physiology-heart and Circulatory Physiology | 2002
Dan P. Stephens; Lee Ann T. Bennett; Ken Aoki; Wojciech A. Kosiba; Nisha Charkoudian; John M. Johnson
American Journal of Physiology-regulatory Integrative and Comparative Physiology | 2001
Ken Aoki; Dan P. Stephens; John M. Johnson
American Journal of Physiology-regulatory Integrative and Comparative Physiology | 2006
Ken Aoki; Dan P. Stephens; Kun Zhao; Wojciech A. Kosiba; John M. Johnson
Journal of Applied Physiology | 2003
Ken Aoki; Dan P. Stephens; Adham R. Saad; John M. Johnson
Archive | 2015
E. M. Brooks-Asplund; W. L. Kenney; Nisha Charkoudian; Dan P. Stephens; Kenna C. Pirkle; Wojciech A. Kosiba; John M. Johnson; Nina S. Stachenfeld; Celso Silva; David L. Keefe
Collaboration
Dive into the Dan P. Stephens's collaboration.
University of Texas Health Science Center at San Antonio
View shared research outputsUniversity of Texas Health Science Center at San Antonio
View shared research outputsUniversity of Texas Health Science Center at San Antonio
View shared research outputs